—

Grifols S.A. (GRF.MC) — the peer cohort

As of 2026-11-17 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Grifols S.A. ranks 13 of 13 in its cohort on the Closelooknet composite (53/100) — the cohort is led by Halozyme Therapeutics Inc at 71/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
GRF.MC Grifols S.A. 53 84 44 73 ok 1.1%
LLY Eli Lilly and Company 64 89 90 22 watch 3%
SAN.PA Sanofi SA 64 76 69 63 bull 0.8%
ORNAV.HE Orion Oyj A 63 95 84 28 ok 1%
ORNBV.HE Orion Oyj B 63 94 84 28 ok 2.3%
NVO Novo Nordisk A/S 56 31 86 73 neutral 32.8%
AZN.L AstraZeneca PLC 55 61 75 45 info 10.8%
ROVI.MC Laboratorios Farmaceuticos ROVI 63 63 74 42 info 19.6%
ALM.MC Almirall S.A. 54 45 41 63 info 22.9%
HALO Halozyme Therapeutics Inc 71 67 94 49 info 28.4%
ONC BeOne Medicines AG 66 89 68 29 ok 2.7%
REGN Regeneron Pharmaceuticals Inc 65 90 73 47 neutral 4%
ANN.AU Ansell Ltd 64 97 47 50 ok 1.5%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-17

Quick answers

Who are Grifols S.A.'s peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Sanofi SA (SAN.PA), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Novo Nordisk A/S (NVO), AstraZeneca PLC (AZN.L), Laboratorios Farmaceuticos ROVI (ROVI.MC), Almirall S.A. (ALM.MC) and others, as of 2026-11-17.

How does GRF.MC score against its peers?

Grifols S.A.'s composite reads 53/100, ranking 13 of 13 in its cohort as of 2026-11-17; the cohort's highest composite is Halozyme Therapeutics Inc at 71/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.